United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $259.70, for a total value of $934,920.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $33,761. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

United Therapeutics Stock Performance

UTHR stock opened at $266.22 on Wednesday. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The firm has a market cap of $11.81 billion, a P/E ratio of 12.59 and a beta of 0.54. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $266.65. The stock’s 50 day simple moving average is $238.38 and its 200 day simple moving average is $229.88.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business’s revenue was up 33.7% compared to the same quarter last year. During the same period in the prior year, the company posted $4.86 EPS. As a group, equities research analysts predict that United Therapeutics Co. will post 23.88 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Headlands Technologies LLC raised its position in shares of United Therapeutics by 53.7% during the 1st quarter. Headlands Technologies LLC now owns 1,131 shares of the biotechnology company’s stock valued at $260,000 after acquiring an additional 395 shares in the last quarter. Inspire Investing LLC raised its position in shares of United Therapeutics by 17.6% during the 1st quarter. Inspire Investing LLC now owns 7,280 shares of the biotechnology company’s stock valued at $1,672,000 after acquiring an additional 1,092 shares in the last quarter. Sei Investments Co. increased its position in United Therapeutics by 3.2% in the first quarter. Sei Investments Co. now owns 37,257 shares of the biotechnology company’s stock worth $8,562,000 after buying an additional 1,149 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in United Therapeutics in the first quarter worth $12,567,000. Finally, Forsta AP Fonden increased its position in United Therapeutics by 14.5% in the first quarter. Forsta AP Fonden now owns 8,700 shares of the biotechnology company’s stock worth $1,999,000 after buying an additional 1,100 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on UTHR shares. Oppenheimer increased their target price on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. SVB Leerink started coverage on United Therapeutics in a research report on Monday, February 5th. They issued an “outperform” rating and a $330.00 price objective on the stock. Leerink Partnrs reissued an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. Wells Fargo & Company boosted their price target on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research report on Thursday, March 7th. Finally, The Goldman Sachs Group upped their price target on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $308.78.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.